Genetically druggable targets for MAPK-activated colorectal cancer by a two-sample mendelian randomization analysis

Area of Science:

• Oncology
• Genetics
• Immunology

Background:

• Colorectal cancer (CRC) is a leading cause of cancer death globally, with increasing incidence projected.
• MAPK signaling pathways, often activated by RAS oncogene mutations, are implicated in over 60% of CRC cases and present therapeutic challenges.
• Current treatment options for MAPK-activated CRC are limited due to the 'undruggable' nature of these mutations.

Purpose of the Study:

• To investigate the potential causal relationship between plasma protein levels and the risk of developing MAPK-activated colorectal cancer.
• To identify novel plasma protein biomarkers for early detection and therapeutic intervention in CRC.
• To explore new avenues for treating difficult-to-target MAPK-activated CRC.

Main Methods:

• Utilized a two-sample Mendelian randomization (MR) approach.
• Integrated protein quantitative trait loci (pQTL) data with genetic associations for CRC.
• Analyzed associations between specific plasma proteins and MAPK-activated CRC risk.

Main Results:

• Identified four plasma proteins significantly associated with an increased risk of MAPK-activated CRC.
• These proteins include MHC class I polypeptide-related sequence B (MICB), complement C4A, complement C4B, and interleukin-21 (IL-21).
• The findings suggest a potential role for these proteins in CRC pathogenesis and progression.

Conclusions:

• MHC class I polypeptide-related sequence B (MICB), complement C4A, C4B, and IL-21 may serve as valuable diagnostic markers for MAPK-activated CRC.
• These plasma proteins represent promising therapeutic targets for developing novel interventions against CRC.
• Further research is warranted to validate these findings and explore their clinical utility in CRC management.